Description

of

Clinical Trial

Type of

Clinical Trial

Institution

Estimated

Start Date

Estimated End Date

Number of Patients

in Trial

Study Objective

Clinical Update

NCT No.

LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer

Phase 1b

City of Hope and Sarah Cannon

March 2021

March 2026

14 to 36

Determine RP2D

Three patients entered

NCT04560972

LB-100 combined with doxorubicin in sarcoma

Phase 1b

GEIS

June 2023

June 2024

9 to 18

Determine MTD and RP2D

One patient entered

NCT05809830

Doxorubicin with or without LB-100 in sarcoma

Randomized Phase 2

GEIS

July 2024

June 2026

150

Determine efficacy: PFS

Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)

NCT05809830

LB-100 combined with dostarlimab in ovarian clear cell carcinoma

Phase 1b/2

MD Anderson

March 2024

December 2025

21

Determine the survival of patients with ovarian clear cell carcinoma

No patients entered at September 30, 2023

NCT06065462